A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.

Patient-derived multiple myeloma (MM) cells are difficult to establish in culture or propagate in vivo in murine model. Here, we describe a zebrafish xenograft model that permits rapid, reliable growth of human MM cells injected into the perivitelline space of albino zebrafish (Casper) embryos 48 hours postfertilization. MM1S and MM1R MM cell lines and primary CD138(+) MM cells were stained with CM-Dil red fluorescent dye and suspended in Matrigel prior to their injection. The cells grew at the site of injection and disseminated throughout the developing embryos and larvae. Tumor size was quantified by fluorescent microscopy, and cell fate was followed for 4 days. All of the cell line xenografts showed responses similar to those previously observed with in vitro assays. CD138(+) plasma cell xenografts derived from MM patients also grew and were inhibited by the same drugs patients had responded to clinically. Using this technique, we can assess drug sensitivity or resistance with a small number of MM cells in a short period. This raises the possibility that one might be able to assess drug sensitivity in real time with readily obtainable clinical samples.

[1]  N. Iwanami Zebrafish as a model for understanding the evolution of the vertebrate immune system and human primary immunodeficiency. , 2014, Experimental hematology.

[2]  N. Munshi,et al.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. , 2014, Blood.

[3]  Yi Li,et al.  Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma , 2014, Leukemia.

[4]  A. Palucka,et al.  Development and function of human innate immune cells in a humanized mouse model , 2014, Nature Biotechnology.

[5]  P. Parren,et al.  Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. , 2012, Blood.

[6]  N. Munshi,et al.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo , 2010, British journal of haematology.

[7]  L. Zon,et al.  Transparent adult zebrafish as a tool for in vivo transplantation analysis. , 2008, Cell stem cell.

[8]  P. L. Bergsagel,et al.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. , 2008, Cancer cell.

[9]  N. Munshi,et al.  Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. , 2007, Blood.

[10]  A. Protopopov,et al.  The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis , 2007, Cancer cell.

[11]  T. Libermann,et al.  Antimyeloma activity of heat shock protein-90 inhibition. , 2005, Blood.

[12]  Paul Richardson,et al.  Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. , 2004, Blood.

[13]  Z. Gong,et al.  Development and maturation of the immune system in zebrafish, Danio rerio: a gene expression profiling, in situ hybridization and immunological study. , 2004, Developmental and comparative immunology.